<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>j. res. pharm.</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Journal of Research in Pharmacy</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2630-6344</issn>
                                                                                            <publisher>
                    <publisher-name>Marmara University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Pharmaceutical Sciences</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Eczacılık Bilimleri</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>Formulation development and evaluation of modified oral drug delivery system of tolterodine tartrate microsponges</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0003-0133-7070</contrib-id>
                                                                <name>
                                    <surname>Gade</surname>
                                    <given-names>Ramani</given-names>
                                </name>
                                                                    <aff>Department of pharmaceutics, Priyadarshini Institute of Pharmaceutical Education and Research</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-2443-2225</contrib-id>
                                                                <name>
                                    <surname>Nama</surname>
                                    <given-names>Sreekanth</given-names>
                                </name>
                                                                    <aff>Department of pharmaceutics, Priyadarshini Institute of Pharmaceutical Education and Research</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Avula</surname>
                                    <given-names>Prameela Rani</given-names>
                                </name>
                                                                    <aff>Department of Pharmaceutics, Acharya Nagarjuna University</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20250628">
                    <day>06</day>
                    <month>28</month>
                    <year>2025</year>
                </pub-date>
                                        <volume>26</volume>
                                        <issue>5</issue>
                                        <fpage>1138</fpage>
                                        <lpage>1155</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20220310">
                        <day>03</day>
                        <month>10</month>
                        <year>2022</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20220413">
                        <day>04</day>
                        <month>13</month>
                        <year>2022</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2010, Journal of Research in Pharmacy</copyright-statement>
                    <copyright-year>2010</copyright-year>
                    <copyright-holder>Journal of Research in Pharmacy</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>The present study was carried out with the objective to formulate and evaluate a multi particulate drug delivery system of Tolterodine Tartrate microsponges by the Quashi emulsion diffusion method. Response Surface Methodology (RSM) with Central Composite Design (CCD) was applied to determine the effects of five independent variables, including the amount of retarding polymers (mg), internal phase volume (ml), emulsifier (W/V%), and rotation speed (RPM). The results showed that the optimized amounts of formulation ingredients for microsponge extraction retardant (Eudragit RSPO: 209.55 mg, HPMCK4M: 121.07 mg), volume of internal phase (in equal ratio), i.e. (dichloromethane : ethanol = 36. 89 ml), emulsifier (dibutyl phthalate: 1.44 w/v%) with process variable revolutions per minute (rpm): 750 for production yield, drug inclusion, particle size and percent drug release in time interval of 1, 2, 4 and 8 hours. Die aus der optimierten Formulierung gewonnenen In-vitro-Freisetzungsdaten wurden in verschiedene kinetische Modelle eingepasst. Die optimierte Formulierung zeigte die gewünschte prozentuale Ausbeute (94,90 %), Medikamenteneinschluss (97,56 %), Partikelgröße (194,00 μm), kumulative prozentuale Wirkstofffreisetzung in der ersten, zweiten, vierten und achten Stunde mit 20,74 %, 40,85 %, 71,02 % bzw. 91,02 %. Die Tabletten zeigten eine anfängliche explosionsartige Freisetzung, der eine allmählichere Phase der verlängerten Freisetzung (ER) vorausging, die einer Geschwindigkeitskinetik erster Ordnung mit einem Higuchi-Mechanismus des Diffusionsprozesses folgte. Schlussfolgerung: Tabletten mit verlängerter Freisetzung von Tolterodintartrat-Mikroschwämmen wurden erfolgreich mit Hilfe der Quasi-Emulsionsdiffusionstechnik entwickelt. Die Response-Surface-Methode mit zentralem Verbunddesign erleichterte die Formulierung und Optimierung des modifizierten oralen Wirkstoffabgabesystems von Tolterodintartrat.</p></abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>response surface method -1</kwd>
                                                    <kwd>  central composite design -2</kwd>
                                                    <kwd>  Tolterodine tartrate -3</kwd>
                                                    <kwd>  modified drug delivery systems -4</kwd>
                                                    <kwd>  microsponges -5</kwd>
                                            </kwd-group>
                            
                                                                                                                        </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">[1] Kapoor D, Vyas RB, Lad C, Patel M, Tyagi B. A Review on Microsponge Drug Delivery system. J. Drug. Del. Ther. 2014; 4 (5) : 29-35. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">[2] Osmani RA, Aloorkar NH, Thaware BU, Kulkarni PK, Moin A , Hani U , Srivastava A, Bhosale RR. Microsponge based drug delivery system for augmented gastroparesis therapy. Formulation development and evaluation. Asian. J. Pharm Sci.2015; 10 (5) : 442-51. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">[3] Pradhan R, Kim Y–II, Chang SW, Kim JO. Preparation and evaluation of once-daily sustained-release coated tablets of tolterodine-l-tartrate. Int. J.Pharm 2013; 460 (1-2) : 205-11. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">[4] Raghuvanshi S, Pathak K. Bioadhesive floating microsponges of cinnarizine as novel gastroretentive delivery: Capmul GMO bioadhesive coating versus acconon MC 8-2 EP/NF with intrinsic bioadhesive property. Int J Pharm Investig. 2016 ;6 (4) : 181-193. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">[5] USFDA; United States Food Drug Administrations Dissolution Methods Database | FDA (Accessed on Febraury 2, 2022).</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">[6] Crcarevska M S, Dimitrovska A , Sibinovska N , Mladenovska K , Slavevska RR , Glavas M D .Implementation of quality by design principles in the development of microsponges as drug delivery carriers. Identification and optimization of critical factors using multivariate statistical analyses and design of experiments studies. Int. J. Pharmaceutics. 2015; 489 (1-2):58-72. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">[7] Saini R, Singh SK, Verma PRP. Evaluation of carvedilol-loaded microsponges with nanometric pores using response surface methodology. J. Exp. Nano science. 2014; 9 (8) , 831-850. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">[8] Rajabalaya R, Yee MC , Chellian J, Chakravarthi S, David S R. Transdermal delivery of tolterodine tartrate for overactive bladder treatment. In vitro and in vivo evaluation. Acta. Pharm. 2017; 67 (3) :325–339. [CrossRef] .</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">[9] Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug. Dev. Industrial Pharmacy, 2017; 43 (6):16. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">[10] Jain V, Singh R. Dicyclomine-loaded Eudragit -based Microsponge with Potential for Colonic Delivery: Preparation and Characterization. Trop. J. Pharm. Res. 2010; 9 (1) : 67-72. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">[11] Moin A, Deb TK, Osmani RA, Bhosale RR, Hani U. Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm. 2016; 7 (2):39-48. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">[12] Sonali , Singh R P, Prajapati S K. Formulation and evaluation of prednisolone loaded microsponges for colon drug delivery: In-vitro and pharmacokinetic study. Int. J .Pharm. Sci. Res. 2014; 5 (5): 1994-2005. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">[13] Desavathu M, Pathuri R, Chunduru M. Design, Development and Characterisation of Valsartan Microsponges by Quasi Emulsion Technique and the Impact of Stirring Rate on Microsponge Formation. J. App. Pharm. Sci. 2017; 7 (1) : 193-198. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">[14] Kumar CB, Narayanan B L, Chandrasekar M, Malairajan P, Kumar EP. Development and Validation of RP-HPLC Method for the Quantitative Estimation of Tolterodine Tartrate in Capsule Formulation. RGUHS. J. Pharm. Sci. 2013; 3 (3) :58-64. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">[15] Netal A, Bajaj A, Madan M. Development of microsponges for topical delivery of mupirocin. AAPS PharmSciTech. 2009;10 (2) : 402-9. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">[16] Bansode AS, Kute VB, Vethekar KS, Kote PS, Varhadi MK,Bansode AS, Jadhav SL, Devhadrao NV. Formulation, Development and Evaluation of Microsponge Loaded Topical Gel of Nystatin. J. d rug. Deliv. ther. 2019; 9 (2-s), 451-461. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">[17] Mohammad KI , Singh PK , Mohd. S , Iqubal A, Singh M. Recent advances in Direct Compression Technique for Pharmaceutical Tablet Formulation. Int. J. Pharm. Res. Dev. 2014; 6 (1): 049 – 057.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">[18] Basu B, Bagadiya A, Makwana S, Vora V, Batt D, Dharamsi A. Formulation and evaluation of fast dissolving tablets of cinnarizine using superdisintegrant blends and subliming material. J. Adv. Pharm. Technol .Res. 2011; 2 (4) : 266-273. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">[19] Mhamunkar SM, Srinivasan G, Khan T, Bhoir SI, Comparative dissolution studies of an extended release formulation of Tolterodine tartrate and Tamsulosin Hcl. Bio.Med. Rx. 2013; 1( 3), 333-338.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">[20] Chime SA, Onunkwo G, Onyishi I. Kinetics and mechanisms of drug release from swellable and non swellable matrices: A review. Res. J. Pharm, Biol and Cheml Sci. 2013; 4 (2),97-103.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">[21] Picciotto M. Reporting on Experimental Design and Statistical Analysis. J Neurosci. 2017; 37 (14) : 3737. [CrossRef]</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">[22]. Cherukuri S R, Ravella V N ; Modified release Tolterodine formulations. W02009/140557 A2. 2009-11-19.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
